Identification of an Adduct Impurity of an Active Pharmaceutical Ingredient and a Leachable in an Ophthalmic Drug Product Using LC-QTOF.
Impurity investigations are important in pharmaceutical development to ensure drug purity and safety for the patient. The impurities typically found in drug products are degradants or reaction products of the active pharmaceutical ingredient (API) or leachable compounds from the container closure system. However, secondary reactions may also occur between API degradants, excipient impurities, residual solvents, and leachables to form adduct impurities. We hereby report an adduct-forming interaction of API (moxifloxacin) with a leachable compound (ethylene glycol monoformate) in moxifloxacin ophthalmic solution. The leachable compound originated from a low-density polyethylene bottle used in the packaging of drug products. The adduct impurity was tentatively identified as 1-cyclopropyl-6-fluoro-7-(1-(2-(formyloxy)ethyl) octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (C24H28FN3O6, MW = 473.19621) using accurate mass LC-QTOF analysis. The mass accuracy error between the theoretical mass and the experimental mass of an impurity was found to be 0.2 ppm. An MS/MS analysis was utilized to provide mass spectrometry fragments to support verification of the proposed structure.
['Gollapalli|Ramarao|R|', 'Singh|Gagandeep|G|', 'Blinder|Alejandro|A|', 'Brittin|Jeremiah|J|', 'Sengupta|Arijit|A|', 'Mondal|Bikash|B|', 'Patel|Milan|M|', 'Pati|Biswajit|B|', 'Lee|James|J|', 'Ghode|Amit|A|', 'Kote|Mahesh|M|']
D002851:Chromatography, High Pressure Liquid D004340:Drug Contamination D004349:Drug Packaging D009883:Ophthalmic Solutions D004364:Pharmaceutical Preparations D053719:Tandem Mass Spectrometry
adduct active pharmaceutical ingredient leachables LC-QTOF low-density polyethylene extractables